<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="https://dochub.sk.ru/utility/feedstylesheets/atom.xsl" media="screen"?><feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru"><title type="html">biomedlibrary - Блог</title><subtitle type="html" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/atom.aspx</id><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/default.aspx" /><link rel="self" type="application/atom+xml" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/atom.aspx" /><generator uri="http://telligent.com" version="7.6.9.38140">Telligent Community 7.6.9.38140 (Build: 7.6.9.38140)</generator><updated>2015-02-02T18:49:37Z</updated><entry><title>Разработка инновационных лекарственных препаратов в России: возможности, барьеры и практики</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/10/13/razrabotka-innovacionnyh-lekarstvennyh-preparatov-v-rossii-vozmozhnosti-barery-i-praktiki.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/10/13/razrabotka-innovacionnyh-lekarstvennyh-preparatov-v-rossii-vozmozhnosti-barery-i-praktiki.aspx</id><published>2015-10-13T10:17:00Z</published><updated>2015-10-13T10:17:00Z</updated><content type="html">Данное исследование проведено в 2014-&amp;shy;‐2015 годах в рамках совместного проекта Университета Маастрихта (Maastricht University, Нидерланды) и Национального исследовательского Томского государственного университета (Российская Федерация) по изучению...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/10/13/razrabotka-innovacionnyh-lekarstvennyh-preparatov-v-rossii-vozmozhnosti-barery-i-praktiki.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=44911&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Voronkov Viktor</name><uri>https://dochub.sk.ru/members/VVoronkov/default.aspx</uri></author><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /></entry><entry><title>The review of Russian Biotech industry</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/the-review-of-russian-biotech-industry.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/the-review-of-russian-biotech-industry.aspx</id><published>2015-07-28T13:28:00Z</published><updated>2015-07-28T13:28:00Z</updated><content type="html">Pharma Executive 
 The review of Russian Biotech industry and most important players in the beginning of 2014.(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/the-review-of-russian-biotech-industry.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43923&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="R&amp;amp;D" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/R_2600_amp_3B00_D/default.aspx" /><category term="prix gallen" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/prix+gallen/default.aspx" /><category term="Russia" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Russia/default.aspx" /><category term="Pharma" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Pharma/default.aspx" /><category term="pharma 2020" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/pharma+2020/default.aspx" /><category term="en" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/en/default.aspx" /><category term="СЕЛЕКТА (РУС)" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/_210415041B0415041A0422041004_+_28002004230421042900_/default.aspx" /><category term="rusnano" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/rusnano/default.aspx" /><category term="chemrar" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/chemrar/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /></entry><entry><title>From vision to decision</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/from-vision-to-decision.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/from-vision-to-decision.aspx</id><published>2015-07-28T13:21:58Z</published><updated>2015-07-28T13:21:58Z</updated><content type="html">PWC 
 PwC vision of Pharma 2020 pillars. The description of 3 fundamental challenges: rising customer expectation, poor scientific productivity, cultural sclerosis.(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/from-vision-to-decision.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43922&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="Russia" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Russia/default.aspx" /><category term="Pharma" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Pharma/default.aspx" /><category term="pharma 2020" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/pharma+2020/default.aspx" /><category term="en" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/en/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /><category term="healthcare" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/healthcare/default.aspx" /></entry><entry><title>Исследование медико-биологической отрасли и системы здравоохранения в России. 2013–2014 годы</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/issledovanie-medikobiologicheskoy-otrasli-i-sistemy-zdravoohraneniya-v-rossii-2013_1320_2014-gody.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/issledovanie-medikobiologicheskoy-otrasli-i-sistemy-zdravoohraneniya-v-rossii-2013_1320_2014-gody.aspx</id><published>2015-07-28T13:20:00Z</published><updated>2015-07-28T13:20:00Z</updated><content type="html">Ernst &amp;amp; Young 
 Качественное исследование (методом экспертный опроса) динамики развития медико-биологической отрасли и системы здравоохранения за 2012-2013 годы.(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/issledovanie-medikobiologicheskoy-otrasli-i-sistemy-zdravoohraneniya-v-rossii-2013_1320_2014-gody.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43921&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="Russia" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Russia/default.aspx" /><category term="Pharma" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Pharma/default.aspx" /><category term="pharma 2020" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/pharma+2020/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /><category term="healthcare" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/healthcare/default.aspx" /></entry><entry><title>Исследование фармацевтической отрасли в России</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/issledovanie-farmacevticheskoy-otrasli-v_A000_rossii.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/issledovanie-farmacevticheskoy-otrasli-v_A000_rossii.aspx</id><published>2015-07-28T13:18:00Z</published><updated>2015-07-28T13:18:00Z</updated><content type="html">Ernst &amp;amp; Young 
 Качественное исследование (методом экспертный опроса) динамики развития российской фарцмацевтической отрасли за 2010-2012 годы. Первые результаты ФЦП &amp;quot;Фарма 2020&amp;quot;.(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/issledovanie-farmacevticheskoy-otrasli-v_A000_rossii.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43919&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="Russia" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Russia/default.aspx" /><category term="Pharma" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Pharma/default.aspx" /><category term="pharma 2020" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/pharma+2020/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /></entry><entry><title>Site Selection for Life Sciences Companies</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/site-selection-for-life-sciences-companies.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/site-selection-for-life-sciences-companies.aspx</id><published>2015-07-28T13:16:00Z</published><updated>2015-07-28T13:16:00Z</updated><content type="html">KPMG in association with Venture Valuation 
 This analysis is aimed at helping entrepreneurs to choose the best possible spot to set up Biotechnology business in EU. The report compares leading EU Life Science Clusters: France, Germany, Ireland, the...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/site-selection-for-life-sciences-companies.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43918&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="R&amp;amp;D" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/R_2600_amp_3B00_D/default.aspx" /><category term="policy" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/policy/default.aspx" /><category term="best practices" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/best+practices/default.aspx" /><category term="nih" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/nih/default.aspx" /><category term="VC" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/VC/default.aspx" /><category term="tech transfer" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/tech+transfer/default.aspx" /><category term="united states" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/united+states/default.aspx" /><category term="legal" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/legal/default.aspx" /><category term="en" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/en/default.aspx" /><category term="commercialization" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/commercialization/default.aspx" /><category term="sbir" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/sbir/default.aspx" /><category term="biotech" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biotech/default.aspx" /><category term="legislation" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/legislation/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /></entry><entry><title>Bioscience Economic Development: Legislative Priorities, Best Practices, and Return on Investment</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/bioscience-economic-development-legislative-priorities-best-practices-and-return-on-investment.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/bioscience-economic-development-legislative-priorities-best-practices-and-return-on-investment.aspx</id><published>2015-07-28T13:13:00Z</published><updated>2015-07-28T13:13:00Z</updated><content type="html">BIO - Biotechnology Industry Organization 
 This report by BIO is a digest of noteworthy public policy strategies and programs to assist policy leaders and their bioscience industry partners in identifying new and innovative measures to create, nurture...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/bioscience-economic-development-legislative-priorities-best-practices-and-return-on-investment.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43917&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="R&amp;amp;D" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/R_2600_amp_3B00_D/default.aspx" /><category term="policy" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/policy/default.aspx" /><category term="best practices" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/best+practices/default.aspx" /><category term="nih" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/nih/default.aspx" /><category term="VC" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/VC/default.aspx" /><category term="tech transfer" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/tech+transfer/default.aspx" /><category term="united states" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/united+states/default.aspx" /><category term="legal" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/legal/default.aspx" /><category term="en" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/en/default.aspx" /><category term="commercialization" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/commercialization/default.aspx" /><category term="sbir" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/sbir/default.aspx" /><category term="biotech" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biotech/default.aspx" /><category term="legislation" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/legislation/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /></entry><entry><title>outh Korea Life Sciences Trend Analysis 2015</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/south-korea-life-sciences-trend-analysis-2015.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/south-korea-life-sciences-trend-analysis-2015.aspx</id><published>2015-07-28T12:45:00Z</published><updated>2015-07-28T12:45:00Z</updated><content type="html">Venture Valuation 
 The analysis of life sciences indusrty in South Korea in 2015. The report discusses key activities, ownership type, financing raised, therapeutic products in the Pipeline of Korea Biotech industry players.(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/south-korea-life-sciences-trend-analysis-2015.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43916&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="SMEs" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/SMEs/default.aspx" /><category term="South Korea" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/South+Korea/default.aspx" /><category term="en" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/en/default.aspx" /><category term="biotech" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biotech/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /><category term="healthcare" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/healthcare/default.aspx" /></entry><entry><title>Venture Valuation - South Korea Life Sciences Trend Analysis 2014</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/venture-valuation--south-korea-life-sciences-trend-analysis-2014.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/venture-valuation--south-korea-life-sciences-trend-analysis-2014.aspx</id><published>2015-07-28T12:32:00Z</published><updated>2015-07-28T12:32:00Z</updated><content type="html">The analysis of life sciences indusrty in South Korea in 2014. The report discusses key activities, ownership type, financing raised, therapeutic products in the Pipeline of Korea Biotech industry players.(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/07/28/venture-valuation--south-korea-life-sciences-trend-analysis-2014.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=43915&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Galiev Rafail</name><uri>https://dochub.sk.ru/members/RGaliev/default.aspx</uri></author><category term="R&amp;amp;D" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/R_2600_amp_3B00_D/default.aspx" /><category term="Cluster" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Cluster/default.aspx" /><category term="medical devices" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/medical+devices/default.aspx" /><category term="South Korea" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/South+Korea/default.aspx" /><category term="Pharma" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/Pharma/default.aspx" /><category term="en" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/en/default.aspx" /><category term="innovations" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/innovations/default.aspx" /><category term="biomed_library" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/biomed_5F00_library/default.aspx" /><category term="healthcare" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/healthcare/default.aspx" /></entry><entry><title>Свободная курица и толченый сверчок</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/09/svobodnaya-kurica-i-tolchenyy-sverchok.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/09/svobodnaya-kurica-i-tolchenyy-sverchok.aspx</id><published>2015-02-09T10:00:06Z</published><updated>2015-02-09T10:00:06Z</updated><content type="html">Уже в ближайшие десятилетия человечеству придется столкнуться с проблемами, от успешного решения которых будет зависеть само его выживание. Если последствия глобального потепления вряд ли приведут к катастрофе, во всяком случае, до конца XXI века, то...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/09/svobodnaya-kurica-i-tolchenyy-sverchok.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=41306&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Melikov Elchin</name><uri>https://dochub.sk.ru/members/ElchinMelikov/default.aspx</uri></author><category term="bmt_test" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/bmt_5F00_test/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /></entry><entry><title>В поисках лекарства от рака Google создала искусственную человеческую кожу</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/09/v-poiskah-lekarstva-ot-raka-google-sozdala-iskusstvennuyu-chelovecheskuyu-kozhu.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/09/v-poiskah-lekarstva-ot-raka-google-sozdala-iskusstvennuyu-chelovecheskuyu-kozhu.aspx</id><published>2015-02-09T09:39:26Z</published><updated>2015-02-09T09:39:26Z</updated><content type="html">Учёные подразделения Google, отвечающего за инновационные разработки в области медицины, в рамках проекта по выявлению онкологических заболеваний на ранних стадиях, создали искусственную человеческую кожу. По словам руководителя исследовательской команды...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/09/v-poiskah-lekarstva-ot-raka-google-sozdala-iskusstvennuyu-chelovecheskuyu-kozhu.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=41304&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Melikov Elchin</name><uri>https://dochub.sk.ru/members/ElchinMelikov/default.aspx</uri></author><category term="bmt_test" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/bmt_5F00_test/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /></entry><entry><title>Расследование РБК: как работает биотехнологический бизнес в России</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/rassledovanie-rbk-kak-rabotaet-biotehnologicheskiy-biznes-v-rossii.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/rassledovanie-rbk-kak-rabotaet-biotehnologicheskiy-biznes-v-rossii.aspx</id><published>2015-02-02T14:59:00Z</published><updated>2015-02-02T14:59:00Z</updated><content type="html">Медицинские биотехнологии &amp;ndash; новая любимая игрушка глобальных инвесторов: второй год подряд отрасль переживает настоящий бум. РБК выяснил, как добывают финансирование и на что надеются российские биотехнологические компании 
 По данным портала FierceBiotech...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/rassledovanie-rbk-kak-rabotaet-biotehnologicheskiy-biznes-v-rossii.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=41214&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Melikov Elchin</name><uri>https://dochub.sk.ru/members/ElchinMelikov/default.aspx</uri></author><category term="bmt_test" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/bmt_5F00_test/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /></entry><entry><title>Ценообразования для стационарных медицинских услуг - G-DRG-System</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/cenoobrazovaniya-dlya-stacionarnyh-medicinskih-uslug--gdrgsystem.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/cenoobrazovaniya-dlya-stacionarnyh-medicinskih-uslug--gdrgsystem.aspx</id><published>2015-02-02T14:51:12Z</published><updated>2015-02-02T14:51:12Z</updated><content type="html">Для расчёта стоимости стационарного лечения в немецких клиниках с начала 2004 года действует единая система ценообразования, так называемая DRG (Diagnosis-Related-Groups - диагностически связанные группы) - система. Цена за пребывание в больнице зависит...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/cenoobrazovaniya-dlya-stacionarnyh-medicinskih-uslug--gdrgsystem.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=41212&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Melikov Elchin</name><uri>https://dochub.sk.ru/members/ElchinMelikov/default.aspx</uri></author><category term="bmt_test" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/bmt_5F00_test/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /></entry><entry><title>Юрий Комаров: Методология разработки экономических стандартов финансирования больничных учреждений.</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/yuriy-komarov-metodologiya-razrabotki-ekonomicheskih-standartov-finansirovaniya-bolnichnyh-uchrezhdeniy.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/yuriy-komarov-metodologiya-razrabotki-ekonomicheskih-standartov-finansirovaniya-bolnichnyh-uchrezhdeniy.aspx</id><published>2015-02-02T14:50:30Z</published><updated>2015-02-02T14:50:30Z</updated><content type="html">В каждой стране, не зависимо от типа и характера системы здравоохранения (бюджетная, страховая, частная, смешанная), финансирование больниц должно осуществляться не спонтанно и стихийно, а на научной основе с помощью специально разработанных стандартов...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/yuriy-komarov-metodologiya-razrabotki-ekonomicheskih-standartov-finansirovaniya-bolnichnyh-uchrezhdeniy.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=41211&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Melikov Elchin</name><uri>https://dochub.sk.ru/members/ElchinMelikov/default.aspx</uri></author><category term="bmt_test" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/bmt_5F00_test/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /></entry><entry><title>DRG И МЭСЫ – КТО КОГО?</title><link rel="alternate" type="text/html" href="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/drg-i-mesy-_1320_-kto-kogo_3F00_.aspx" /><id>https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/drg-i-mesy-_1320_-kto-kogo_3F00_.aspx</id><published>2015-02-02T14:49:37Z</published><updated>2015-02-02T14:49:37Z</updated><content type="html">В ней приняли участие представители Совета Федерации РФ, Минздравсоцразвития России, ФФОМС РФ, страховых компаний и медицинского сообщества, эксперты по экономике здравоохранения, а также эксперты из Германии и Турции, где система DRG успешно внедрена...(&lt;a href="https://dochub.sk.ruhttps://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/2015/02/02/drg-i-mesy-_1320_-kto-kogo_3F00_.aspx"&gt;read more&lt;/a&gt;)&lt;img src="https://dochub.sk.ru/aggbug.aspx?PostID=41210&amp;AppID=10216&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</content><author><name>Melikov Elchin</name><uri>https://dochub.sk.ru/members/ElchinMelikov/default.aspx</uri></author><category term="bmt_test" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/bmt_5F00_test/default.aspx" /><category term="ru" scheme="https://dochub.sk.ru/foundation/biomed/biomedlibrary/b/weblog/archive/tags/ru/default.aspx" /></entry></feed>